Navigation Links
PharmAthene and Theraclone Sciences Announce Merger Agreement to Create Diversified Biologics Company Targeting Government and Commercial Markets
Date:8/1/2013

Theraclone's unique mAb discovery platform has captured the interest of large Pharma, with the potential to yield multiple collaboration opportunities for various disease targets. The company has established discovery collaborations with Pfizer, Zenyaku Kogyo and the International AIDS Vaccine Research Initiative.  For additional information, visit www.theraclone-sciences.com.

PharmAthene Forward-Looking Statement Disclosure

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "will"; "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. Such statements include, but are not limited to those referring to the potential for the generation of value, ability to leverage funding sources, potential for revenue, and potential for growth.  PharmAthene disclaims any intent or obligation to update these forward-looking statements.  Risks and uncertainties include, among others, failure to obtain necessary shareholder approval for the proposed merger with Theraclone and the matters related thereto; failure of either party to meet the conditions to closing of the transaction; delays in completing the transaction and the risk that the transaction may not be completed at all; failure to realize the anticipated benefits from the transaction or delay in realization thereof; the businesses of PharmAthene and Theraclone may not be combined successfully, or suc
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. PharmAthene Reports First Quarter 2013 Financial And Operational Results
2. New Data Show PharmAthenes Recombinant Bioscavenger Binds To A Broad Spectrum Of Chemical Nerve Agents
3. SIGA Technologies Files Notice of Appeal in PharmAthene Litigation
4. PurThread Technologies Welcomes Life Sciences Veterans to CEO and Board Positions
5. Earnings Releases, Investment Plans, Commencement of Clinical Trials, and FDA Applications Brighten Outlook - Research Report on Bard, Centene, Exact Sciences, Ironwood, and Merrimack
6. Thomson Reuters Life Sciences Cortellis Competitive Intelligence Reaches Content Milestones
7. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
8. BioDelivery Sciences Announces the Hiring of Adrian Hepner, M.D. as Vice President of Clinical Research & Regulatory Affairs
9. MELA Sciences, Inc., A Leader In The Fight Against Melanoma, Hosts Symposium At 8th World Congress Of Melanoma
10. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
11. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
(Date:1/14/2014)... a manufacturer of ergonomically designed laboratory equipment for research, ... Japan to sell and service the Hitachi brand ... utilize its network of sales professionals throughout the United ... assistance in application use, product benefits and features, options and accessories, ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... First Commercial Market to Demonstrate Test,s Potential for ... ... ASA (OSL: DIAG) and Applied Biosystems Inc. (NYSE: ABI ) today,announced ... The test searches for a unique gene expression signature,identified by DiaGenic using ...
... Drug was Well-Tolerated, Significantly Inhibited ... on Monday, November 10 at 8:30 ... a.m. ET-, ... VIAP ), a biotechnology company focused on,the development of compounds for the treatment ...
Cached Medicine Technology:Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 2Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 3VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 2VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 3VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 4VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 5VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 6VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 7VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 8
(Date:4/18/2014)... Harvard neuroscientists have made a discovery that turns 160 ... electrical insulating material long known to be essential for ... nerve cells, is not as ubiquitous as thought, according ... of the Harvard Stem Cell Institute (HSCI) and the ... collaboration with Professor Jeff Lichtman, of Harvard,s Department of ...
(Date:4/18/2014)... your worst memories? How did it make you feel? ... negative personal experience, such as how sad you were ... distress, especially when you can,t stop thinking about it. ... about the context of the memories, rather than how ... to alleviate the negative effects of these memories, a ...
(Date:4/18/2014)... Simon Fraser University psychologists have made a brain-related ... of attention-deficit disorders. , This discovery opens up ... hinder or suppress a specific brain activity that ... distraction. , The Journal of Neuroscience ... by John McDonald, an associate professor of psychology ...
(Date:4/18/2014)... is available in French . ... surgical practice and regenerative medicine. A team led by ... (CNRS/ESPCI Paris Tech) and Didier Letourneur from the Laboratoire ... has just demonstrated that the principle of adhesion by ... to repair soft-tissue organs and tissues. This easy-to-use gluing ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... potential role of Eph receptor and ephrin ligand family ... other Eph receptors, EphA4 is distinguished by its ability ... type B ephrins. EphA4 reportedly forms a hetero receptor ... downstream signal transduction. However, alterations of EphA4 are not ...
... association of DM2 with solid tumors, and particularly with ... reported increased mortality rates for neoplastic diseases in patients ... diabetes and development of HCC, and the clinical and ... not been well examined. , A research article to ...
... 29 Abbott (NYSE: ABT ),will present at ... Nov. 12. Thomas C. Freyman, executive vice president, finance,and ... company at 5,p.m. CST., A live audio webcast ... Web site at http://www.abbottinvestor.com . An,archived edition of ...
... PRUSSIA, Pa., Oct. 29 HighPoint,Solutions LLC, a premier ... of its growth strategy, it has expanded its,presence in ... new location will,be at 8750 W. Bryn Mawr, Suite ... located near O,Hare International,Airport., Glenn Becker, HighPoint Solutions, ...
... N.J., Oct. 29 Derma Sciences, Inc.,(OTC Bulletin Board: ... it will present at the upcoming Rodman & Renshaw ... Palace Hotel in,New York City. The Company is scheduled ... Adams room located on the 4th floor., Management ...
... Drive Company,s Latest Learning Technology, ORLANDO, Fla., ... a leading provider of educational enterprise technology,announced today ... Release 9.0,featuring nearly 50 institutions that are now ... of the Beta program are evaluating and providing ...
Cached Medicine News:Health News:If the diabetes has a direct carcinogenetic effect? 2Health News:HighPoint Solutions Expands with New Chicago Office 2Health News:Derma Sciences to Present at The Rodman & Renshaw 10th Annual Healthcare Conference 2Health News:Blackboard Announces Launch of Beta Program 2Health News:Blackboard Announces Launch of Beta Program 3Health News:Blackboard Announces Launch of Beta Program 4
Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
Used for emergency airway access when conventional endotracheal intubation cannot be performed....
... Standard/Conventional. Stainless steel. Lamp supplied with ... high quality standard incandescent laryngoscope blades. The ... refined through many years of use the ... are manufactured to exacting specifications from the ...
... Blade. Stainless Steel. Lamp supplied with ... of high quality standard incandescent laryngoscope ... have been continually refined through many ... to minimize maintenance requirements. They are ...
Medicine Products: